Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
AstraZeneca
Julphar
Baxter
Chinese Patent Office
UBS
US Army
Mallinckrodt
Novartis

Generated: January 18, 2018

DrugPatentWatch Database Preview

Supernus Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for SUPERNUS PHARMS, and when can generic versions of SUPERNUS PHARMS drugs launch?

SUPERNUS PHARMS has two approved drugs.

There are sixteen US patents protecting SUPERNUS PHARMS drugs. There is one tentative approval on SUPERNUS PHARMS drugs.

There are twenty-five patent family members on SUPERNUS PHARMS drugs in ten countries and one supplementary protection certificate in one country.

Summary for Supernus Pharms
International Patents:25
US Patents:16
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Supernus Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-001 Oct 19, 2012 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-002 Aug 16, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-001 Oct 19, 2012 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-003 Aug 16, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-003 Oct 19, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-003 Aug 16, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-002 Aug 16, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-001 Aug 16, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-002 Aug 16, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-002 Oct 19, 2012 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for SUPERNUS PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Capsules 25 mg, 50 mg, and 100 mg ➤ Subscribe 5/12/2014
➤ Subscribe Extended-release Capsules 200 mg ➤ Subscribe 4/3/2014
➤ Subscribe Extended-release Tablets 150 mg and 300 mg ➤ Subscribe 4/12/2013

Non-Orange Book US Patents for Supernus Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,017,149 Modified release preparations containing oxcarbazepine and derivatives thereof ➤ Subscribe
8,211,464 Modified release preparations containing oxcarbazepine and derivatives thereof ➤ Subscribe
9,119,792 Modified release preparations containing oxcarbazepine and derivatives thereof ➤ Subscribe
9,855,278 Modified release preparations containing oxcarbazepine and derivatives thereof ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Supernus Pharms Drugs

Supplementary Protection Certificates for Supernus Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB95/028 United Kingdom ➤ Subscribe PRODUCT NAME: TOPIRAMATE; REGISTERED: UK 0242/0301 19950718
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Daiichi Sankyo
AstraZeneca
Teva
Argus Health
McKinsey
Dow
Healthtrust
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot